Egle Therapeutics
Biotherapies developer targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases.
3
Funding Rounds
$96.0m
Money raised
Overview
Biotherapies developer targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases.
- Website:
- Business model: B2B
- Headquarters: Paris
- Social accounts: linkedin
| Name | Phone | Social networks | |
|---|---|---|---|
| Lu* Bo**** | - | - |
Funding
Funding series
Funding Series Analysis
The company Egle Therapeutics has raised a total of $96m in funding over 3 rounds.
Key Insights:
- Egle Therapeutics Grant Round, March 2025: $10m
- Egle Therapeutics Series A round: $40m
- Egle Therapeutics October 2021 Funding Round: $46m
Egle Therapeutics Grant Round, March 2025
$10m
Egle Therapeutics Series A round
$40m
Egle Therapeutics October 2021 Funding Round
$46m
Industries
Egle Therapeutics is active in the following industries: